期刊
CANCER CELL
卷 40, 期 6, 页码 597-599出版社
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.017
关键词
-
资金
- National Institutes of Health (NIH) [R01-CA184185, R01-CA233512, R01-CA262121, P01-CA250984, 4, P30-CA076292]
- Florida Department of Health [20B04]
This study demonstrates how tumors can manipulate erythroid progenitors to promote immunosuppression. These reprogrammed cells, similar to myeloid-derived suppressor cells, are associated with poor response to immune-checkpoint inhibitors and tumor-related anemia.
In this issue of Cancer Cell, Long et al. demonstrate that tumors can reprogram erythroid progenitors into myeloid-erythroid cells that promote immunosuppression. Erythroid-differentiated myeloid cells (EDMCs) expand in cancer-bearing individuals, resemble the functionality of myeloid-derived suppressor cells (MDSCs), and correlate with poor response to immune-checkpoint inhibitors (ICIs) and tumor-related anemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据